Business
Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten,Show Sustained Improvements in Clinical Efficacy Endpointsand No Treatment
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten,Show Sustained Improvements in Clinical Efficacy Endpointsand No Treatment Interruptions for Low Ejection Fraction Commercial Readiness Activities Leverage Insights from Market Research to Inform Market Segmentation and Patient-Centric Strategies New Pre-Clinical Data for CK-586 Shows Improved Diastolic Function and Reduced Cardiac Fibrosis in Animal Model of HFpEF; Phase 1 Study Ongoing SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) will provide an update on the company’s cardiac myosin inhibitor programs and plans to build a specialty cardiology franchise today at its virtual Investor and Analyst Day, “New Horizons in Hypercontractility.” The company plans to review the broad development program for aficamten and present new long-term data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM) and highlight commercial readiness activities in advance of the potential approval and launch of aficamten. The company will also present new preclinical data for CK-4021586 (CK-586), a cardiac myosin inhibitor in development for the potential treatment of patients with heart failure with preserved ejection fraction (HFpEF). Today’s event will also feature perspectives from leading physician experts and a patient advocate living with hypertrophic cardiomyopathy (HCM). “Cytokinetics is advancing plans to build a specialty cardiology franchise anchored by aficamten. We believe we have a unique opportunity to address the multiple manifestations of cardiac hypercontractility with both our late-stage programs and our earlier-stage pipeline,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We expect that, if aficamten is approved, our investment in its clinical development program will support the potential to build a foundation rooted in obstructive HCM, expand into non-obstructive HCM, and bridge to HFpEF while also pursuing opportunities in advanced heart failure. We are uniquely positioned to pursue a specialty cardiology franchise and deliver on the promise of our science to bring forward new medicines for patients given the combination of our pioneering leadership in muscle biology, focused cardiology expertise and strong rel...